Prepare
Pre-Approval Inspection readiness
A Pre-Approval Inspection is not a routine surveillance visit. For NDA and ANDA products, and for relevant biologics supplements involving significant manufacturing changes, investigators may arrive with the application in hand to verify that the facility, process, and data support what the submission claims.
PAI readiness means testing the submission against the floor: can the batch records, method validation, scale-up or transfer data, and the people who own them withstand a line-by-line comparison with what FDA may ask to see? Original BLA pre-license inspection readiness is addressed separately in Tailwind Pharma's biologics PLI/BLA service.
FDA inspection announced — or investigators already on site?
Get inspection help nowPAI readiness is a disciplined test of whether the application, the facility, the process, the data, and the people tell the same defensible story. For original BLA pre-license inspection readiness, see Tailwind Pharma's biologics PLI/BLA readiness service.
What the engagement includes
- Application-to-facility gap review: CMC commitments versus actual practice
- Data integrity verification of the batches and records cited in the submission
- Mock PAI using real inspection technique, focused on the application
- SME preparation for the scientists and engineers who will be interviewed
- A prioritized remediation plan sized to the approval timeline
- Inspection-day support when the PAI arrives
When teams call
- An NDA or ANDA is filed and a PAI may be needed
- A biologics supplement involves a significant manufacturing change that may require on-site review
- The facility or process has changed since the submission was written
- Scale-up or tech-transfer data has not been independently verified
- A prior PAI or surveillance inspection produced observations
- The approval date is commercially critical and a delay is not acceptable
How we approach it
Read the application the way the investigator will
PAI investigators verify specific claims: this process, at this scale, with this data. Joseph Lambert evaluated manufacturing submissions as a CDER compliance officer in the Office of Manufacturing Quality, which shapes where the verification pressure lands first.
Verify before FDA does
The most damaging PAI findings are the ones where the site cannot reproduce what the application describes. We test the records, the data trail, and the people before the agency does, while there is still time to correct.
Fix what is fixable inside the timeline
Not every gap can close before approval. We rank findings by their effect on the application and the inspection outcome, so effort goes to the items FDA is most likely to test.
Related services
Common questions on timelines, scope, and cost are answered on the FAQ page, and engagement terms are on pricing.
Tailwind Pharma provides independent advisory services and does not replace the manufacturer's designated Quality Unit or guarantee regulatory outcomes.